CTLA4 and melanoma: Moreover, upon exposure to the HDACi entinostat in combination with azacytidine, the syngeneic mouse melanoma models displayed improved rates of response to both anti-PD-1 and anti-CTLA-4 immunotherapies, and the tumors were eradicated in 80% of the experimental animals [279].